Depression in patients with
rheumatoid arthritis: description, causes and mechanisms.
Keywords: Bone mass density,
Rheumatoid arthritis, DEXA.
Findings supporting the idea that the onset of autoimmunity may be related to gastrointestinal tract are as follows: (1) microbial composition in subjects with early
rheumatoid arthritis differs to controls, with a reduction of certain bacteria belonging to the family Bifidobacterium and Bacteroides [15, 16], and a marked increase of species belonging to the genus Prevotella [17].
Many of the delegates who attended are members of the Middle East
Rheumatoid Arthritis Consortium.
Hospital specialists commonly prescribe disease-modifying anti-rheumatic drugs to minimise the chances of
rheumatoid arthritis becoming worse.
Rheumatoid Arthritis patients and control groups are found to be different in hypertension (p=0.003) and low HDL (p=0.006) significantly, as hypertension was more common in cases whereas low HDL in controls.
(5) Japan College of Rheumatology, Clinical practice guideline of methotrexate for patients with
rheumatoid arthritis: 2016 update version
To investigate the potential risks and benefits of statins in moderate-risk patients with
rheumatoid arthritis, researchers designed the Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with
Rheumatoid Arthritis (TRACE RA), a multi-centre, randomised, double-blind trial comparing the statin atorvastatin with placebo.
Live births per embryo transfer were less likely in women with
rheumatoid arthritis versus those they were in women with no
rheumatoid arthritis, with an adjusted odds ratio of 0.78 (95% confidence interval, 0.65-0.92), according to investigators.
Conclusion: Secondary fibromyalgia is common in patients with
rheumatoid arthritis and needs to be screened out in all patients diagnosed as
rheumatoid arthritis and on subsequent follow up visits, coexisting fibromyalgia affects the disease activity status and this may result into inappropriate and unnecessary changes in treatment plans.
M2 PHARMA-June 19, 2018-AbbVie Releases Positive Outcome Data from Ongoing Upadacitinib Phase 3 Studies in
Rheumatoid Arthritis